Phathom stockholders elect three Class II directors; ratify E&Y as auditor

Phathom Pharmaceuticals, Inc.

Elected Cola (24.1M for), Karbe (25.0M for), Parikh (21.3M for) with 10.8M broker non-votes each.
Ratified Ernst & Young as independent auditor for fiscal 2024: 37.9M for, 124.6K against, 1.1K abstain.
New non-employee directors get initial grant of 21,000 RSUs and options to purchase 35,000 shares.
Annual director equity grant set at 10,500 RSUs and options for 17,500 shares; cash retainers unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.